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      The purpose of the Perspectives in General Physiology 
is to provide a forum where scientifi  c uncertainties or 
controversies can be discussed in an authoritative, yet 
open, manner. 
  The Perspectives are solicited by the editors  —  often 
based on recommendations by members of the edito-
rial advisory board. To frame the issue, two or more 
experts are invited to present brief points of view on 
the problem, which are published consecutively in the 
Journal. The comments and opinions expressed in the 
Perspectives are those of the authors and not necessar-
ily those of the Editors or the Editorial Advisory Board. 
The Perspectives are accompanied by a few editorial 
paragraphs that introduce the problem  —  and invite 
the submission of comments, in the form of letters to 
the editor, which are published in a single, predeter-
mined issue (usually three months after publication of 
the Perspective). 
  In this issue of the Journal, Gregory Kaczorowski, 
Owen McManus, Birgit Priest and Maria Garcia (Merck 
Research Laboratories, Rahway, NJ), Kenneth Rhodes 
and James Trimmer (Biogen Idec, Cambridge, MA, and 
University of California, Davis, CA), Jon Sack, Oleg 
Shamotienko, and Oliver Dolly (Dublin City University, 
Dublin, Ireland), Jens Lundb  æ  k (Technical University 
of Denmark, Lyngby, Denmark), and Stephen Tucker 
and Thomas Baukrowitz (University of Oxford, Oxford, 
UK, and Friedrich Schiller University, Jena, Germany) 
provide different perspectives on the challenges involved 
in the development of new drugs that target ion chan-
nels  —  or any other membrane protein for that matter. 
  The Perspectives were inspired by a workshop on How 
to Drug an Ion Channel, which was organized by Jon 
Sack and Oliver Dolly and held at Dublin City Univer-
sity in July 2007. The contributions to the Perspectives 
represent only a fraction of the presentations at the 
workshop; they were chosen because they focus on a set 
of recurring topics in the discussions at the workshop. 
  The history of drug development has rarely been 
punctuated by triumphs of rational design. Aside from a 
few notable exceptions (e.g., Van Epps, H.L. 2006.  J. Exp. 
Med.   203:259), Pasteur  ’  s statement that   “  In the fi  elds of 
observation chance favors only the prepared mind  ”   
characterizes most successful therapeutic ventures (e.g., 
Ban, T.A. 2006.   Dialogues Clin. Neurosci.   8:335  –  344). The 
serendipitous routes taken by researchers are exempli-
fi  ed by the discoveries of antibiotics to treat bacterial 
infections (Moberg, C.L., and Z.A. Cohn. 1990. Launch-
ing the Antibiotic Era. The Rockefeller University Press, 
New York), diuretics (Eknoyan, G. 1997.   Kidney Int. 
Suppl.   59:S118  –  S126) and calcium channel blockers 
(Fleckenstein, A. 1983.   Circ. Res.   52:I3  –  I16) to treat 
cardiovascular diseases, valproate to treat seizures 
(L  ö  scher 1999 #46890), the sulfonylureas to treat diabetes 
(Kleinsorge, H. 1998.   Exp. Clin. Endocrinol. Diabetes  . 
106:149  –  151), and lithium and chlorpromazine to treat 
mood disorders and psychoses (Jacobsen 1986 #48080). 
Not surprisingly, therefore, drugs were introduced in 
clinical practice without clear understanding of their mo-
lecular target(s) and mechanism(s) of action. Indeed, 
the mechanism(s) underlying many drugs in current 
use, such as valproate (Rosenberg, R. 2007.   Cell. Mol. Life 
Sci.   64:2090  –  2103) or lithium (Quiroz, J.A., T.D. Gould, 
and H.K. Manji. 2004.   Mol. Interv.   4:259  –  272), have yet 
to be fully elucidated. 
  In the genomic era, the focus of pharmaceutical re-
search is on specifi  c molecular targets that are relevant 
for the disease of interest, with potential drug candi-
dates being identifi  ed using appropriate high-through-
put in vitro screens.   Because ion channels play key roles 
in many different physiological processes, they become 
important potential drug targets; they also pose particu-
lar problems because of the existence of numerous 
channel isoforms with differential cellular and subcel-
lular expression, which complicates both the identifi  ca-
tion of the relevant channel isoform(s) that should be 
targeted and the development of drugs with suffi  cient 
selectivity for the intended target(s). 
  A key consideration in drug development thus be-
comes target identifi  cation and validation and, once this 
has been accomplished, the identifi  cation of small mole-
cule lead compounds that allow for exploration by medici-
nal chemistry methods. In this series, Kaczorowski et al. 
summarize the challenges, which include the develop ment 
of appropriate high-throughput screens, using inhibitors 
of voltage-dependent sodium channels as a case study. A 
key conclusion is that it, even in the absence of molecular 
selectivity, is possible to target a desired channel popula-
tion by exploiting state-dependent drug-channel inter-
actions that favor the drug-induced stabilization of a 
specifi  c state in channels with a particular profi  le, such as 
the inactivated state in voltage-dependent channels in rap-
idly fi  ring or partially depolarized cells. 
  Target identifi  cation becomes a particular problem in 
cases where it may be a heterooligomeric combination 
of different subunits, as is the case for many potassium 
channels. Because different heterooligomers may have 
different pharmacological profi  les and cellular expres-
sion, the challenge of target validation becomes acute. 
This challenge is discussed by Rhodes and Trimmer and 
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ciated with dissecting out the underlying mechanism, 
is discussed by Tucker and Baukrowitz, who review the 
complex interplay between polyphosphoinositides and 
other negatively charged lipids and lipid metabolites in 
the regulation of inward rectifi  er potassium channels. 
  Overall, these Perspectives show that ion channel 
function can be altered by many different, nonexclusive 
mechanisms. A perusal of the contributions shows that 
one in general needs to consider, at least fi  ve different 
mechanisms of drug action  —  ranging from the classic 
pore block (1 in Fig. 1), over allosteric regulation due 
to (specifi  c) drug binding to the target protein (2 and 3 
in Fig. 1), to the allosteric regulation that arises from 
(more nonspecifi  c) drug-induced changes in lipid pack-
ing adjacent to the protein (3 and 4 in Fig. 1) and in bi-
layer material properties (5 in Fig. 1). 
  Because a given drug could exert its action by any 
combination of the above mechanisms, and because any 
amphiphilic molecule will adsorb at the bilayer/solution 
interface, one of the challenges in future drug develop-
ment becomes to identify the relative contribution of 
each of these mechanisms to a potential drug  ’  s overall 
effects  —  for then to optimize for the desired drug ef-
fects. It is in context important that drugs with a high 
by Sack et al. Rhodes and Trimmer address the issues in 
a critical analysis of the strengths and potential pitfalls 
associated with the use of antibody-based methods. Sack 
et al. present a complementary approach using concat-
enated potassium channel constructs in which the sub-
units are linked into a single open reading frame, such 
that the subunit stoichiometry and organization is well 
defi  ned and suitable for defi  ning the pharmacological 
profi  le of potassium channels with the equivalent sub-
unit composition. 
  Once a target has been validated, and a suitable drug 
lead has been discovered, determining its mechanism 
of action is rarely trivial. In the case of ion channels, 
maybe the simplest mechanism is the classic         channel or 
pore block, in which the drug in question binds in the 
channel  ’  s pore to block ion movement. In many cases, 
however, a drug modulates channel function by stabiliz-
ing either a nonconducting or a conducting channel 
state (to either inhibit or potentiate channel function), 
through allosteric mechanisms that are distinct from a 
channel, or pore, block. Generally, any molecule or ex-
perimental maneuver that alters the free energy differ-
ence between different channel states, or the kinetics of 
interconversion between different states, will be a mod-
ulator of channel function. The shift between different 
channel states is usually ascribed to different drug affi  n-
ities to the different channel states, but channel func-
tion may be altered by mechanisms that do not involve 
direct binding to the target, as in the screening of inter-
facial charges, which alters the interfacial potential and 
thus the gating of voltage-dependent channels. 
  It is in this context important that many drugs are am-
phiphiles, meaning that they will adsorb at the lipid bi-
layer/solution interface to alter lipid bilayer properties, 
which in turn may alter the free energy difference as-
sociated with membrane protein conformational transi-
tions (Andersen, O.S., and R.E. Koeppe II. 2007.   Annu. 
Rev. Biophys. Biomol. Struct.   36:107  –  130). That is, am-
phiphilic drugs may alter the function of a channel (or 
any other membrane protein) without direct binding 
to the channel. The mechanistic basis for such bilayer-
dependent changes in channel function is discussed by 
Jens Lundb  æ  k, who presents a framework for how to ap-
proach possible bilayer-dependent drug effects due to 
amphiphile-induced changes in bilayer physical prop-
erties  —  by examining how the drug in question alters the 
function of well-characterized reporter channels, such 
as the gramicidin channels, or by testing how amphi-
philes with well-characterized bilayer-modifying affects 
the target channel  ’  s function. In addition to the regula-
tion caused by changes in bilayer physical properties, 
channel function may also be regulated by changes in 
surface density of specifi  c lipids, such as the polyphos-
phoinositides, in which case the distinction between 
specifi  c and nonspecifi  c effects become particularly 
challenging. This regulation, and the challenges asso-
  Figure 1.     Schematic representation of different, nonexclusive 
mechanisms by which one can drug an ion channel: (1) a drug 
may bind in the pore to block ion movement; (2) a drug may 
bind to a site wholly formed by the protein, to either inhibit or 
potentiate the channel function by altering the free energy dif-
ference between different channel states; (3) an amphiphilic 
drug may bind specifi  cally to a defi  ned site composed of both the 
protein and the bilayer lipids in which case its effects could also 
involve changes in the bilayer deformation energy associated with 
channel conformational changes; (4) an amphiphilic drug may 
accumulate nonspecifi  cally at the protein/bilayer interface to al-
ter local lipid packing, and thereby alter the bilayer deformation 
energy contribution to channel  ’  s conformational changes; and 
(5) an amphiphilic drug may adsorb at the lipid bilayer/solution 
interface to alter the bilayer deformation energy associated with 
the channel conformational changes.       397
They may contain no more than one fi  gure, no more 
than 15 references, and no signifi  cant references to un-
published work. Letters should be prepared according 
to the Journal  ’  s instructions and can be submitted elec-
tronically at www.jgp.org, as an e-mail attachment to 
jgp@mail.rockefeller.edu. 
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affi  nity for the lipid bilayer/solution interface, relative 
to sites 1  –  3, may exert a signifi  cant part of their effects 
through mechanisms 4 and 5, which would make them 
promiscuous modulators of membrane protein function. 
  Letters to the editor related to these Perspectives will 
be published in the August 2008 issue of the   Journal of 
General Physiology  . Letters to the editor should be re-
ceived no later than Monday June 25, 2008, in order to 
allow for editorial review. The letters may be no longer 
than two printed pages (approximately six double-
spaced pages) and will be subject to editorial review. 